Demonstrating the superiority of SAPIEN 3 Transcatheter Aortic Valve Implantation (TAVI) compared with SAVR in low-risk patients with severe aortic stenosis. *,1
Download this infographic to read more about:
- The study design
- The primary and secondary endpoints
- How younger patients may benefit from TAVI
*PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery on the primary endpoint (all-cause death, all stroke, and rehospitalisation) and multiple pre-specified secondary endpoints at one year.
Reference
1 Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med. 2019;380(18):1695–1705.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.
PP—EU-4352 v1.0